61.   DepoTech Corp. failed to win the backing of a U.S. Food and Drug Administration advisory panel for its new time-release cancer drug, DepoCyt.

62.   Entremed is a partner with Bristol-Myers Squibb, the dominant player in cancer chemotherapy drugs, to develop angiostatin, and is seeking a partner for endostatin.

63.   Federal investigators believe that hundreds of patients may have received the weakened cancer drugs.

64.   For Novartis Pharmaceuticals, a division of Swiss drug maker Novartis AG, the test is another boost in its drive to increase its stable of cancer drugs.

65.   For four months, she has taken an experimental cancer drug in a clinical trial.

66.   For years, doctors say, the markup on cancer drugs has partly offset the inadequacy of the payments for administering chemotherapy.

67.   Genentech has two successful new cancer drugs, with several more in the pipeline, and will soon seek approval for a new asthma treatment.

68.   Four companies this week will ask a U.S. Food and Drug Administration advisory panel to recommend approval of their cancer drugs.

69.   Gleevec, the promising new cancer drug already approved for treating some leukemia patients, has researchers cautiously optimistic that it might help fight prostate cancer.

70.   Gumbhir described Courtney as a pioneer among Kansas City pharmacists dealing with cancer drugs.